A ‘Regulatory Gap’ exists within the US dietary supplements industry, and recent talk of modernizing the regulations are ways to close that gap, FDA’s Steven Tave said yesterday
The US Food and Drug Administration may be willing to sit down with a company about a possible NDI submission for full-spectrum hemp extracts, says Steve Mister, president and CEO of the Council for Responsible Nutrition (CRN).
FDA has stated it is making ‘substantial progress’ with CBD, and a new enforcement guidance could be very significant for the industry, said NPA’s Dr Daniel Fabricant, but he said the Agency needs to ‘get in the game’ for NDIs.
A US Food and Drug Administration study reveals that a number of the products it tested labeled as ‘bitter orange’ did not meet label claim for synephrine content and more than 10% contained undeclared synthetic ingredients.
The Natural Products Association (NPA) is calling for the US Food and Drug Administration to use import alerts to stop nutritional supplements that fail to comply with New Dietary Ingredient (NDI) regulations.
The year is new and a lot of people are getting out their crystal balls. NutraIngredients-USA is no exception, and here are our top big issues that will impact the dietary supplements industry in this new decade.
Former Food and Drug Administration (FDA) official Sibyl Swift, PhD, has joined the Natural Products Association as its new Senior Vice President for Scientific and Regulatory Affairs.
A paper published today in a prominent medical journal asserts that the law governing dietary supplements is no longer adequate to protect consumers and sweeping changes are needed to keep potentially dangerous new ingredients off the market.
The Court of Appeals for the Eleventh Circuit has paved the way for a potential class action against a supplement brand because of the alleged presence of an illegal ingredient, which rendered the product worthless and gave the plaintiffs standing to...
Legislative challenges to dietary supplements and opportunities for regulatory fine tuning continue even as the industry is distracted, said Steve Mister of CRN.
FDA is continuing to crack down on the legality of CBD when a case comes across its desk, despite a call for an official enforcement discretion policy.
FDA should issue targeted guidances to facilitate the filing of New Dietary Ingredient Notifications, according to comments filed by the American Herbal Products Association.
There are several ingredient lists on FDA’s website that imply some sort of warning to the public. But what's the criteria that decides into which list an ingredient will fall?
Congress should act to create a new law to solve the CBD (cannabidiol) regulatory issue, while simultaneously “closing long-standing gaps” in the oversight of all dietary supplements, according to a new paper by Dr Pieter Cohen and Dr Joshua Sharfstein.
